{"disease":{"id":"tnf","name":"tnf"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in pediatric patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active ulcerative colitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active Crohn's disease in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active ankylosing spondylitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"canakinumab","indication_name":"TNF receptor-associated periodic fever syndrome (TRAPS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ilaris","generic_name":"CANAKINUMAB","company_name":"Novartis Pharms","drug_phase":"marketed","molecular_target":"Interleukin-1 beta","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":59,"revenue":"1369","mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07170904","title":"Dietary Patterns, Inflammation, Zinc Status, and Body Composition in Multi-Ethnic Women of Reproductive Age in Jakarta","phase":"","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Indonesia University","has_results":false},{"nct_id":"NCT05433597","title":"A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":172,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03747068","title":"The Influence of Biologcal Treatment on the Short-Term Complications of Surgery in Patients With Inflematory Bowel Disease.","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"HaEmek Medical Center, Israel","has_results":false},{"nct_id":"NCT07237906","title":"Neutropenia With TNF-α Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Burak Ugur Cetin","has_results":false},{"nct_id":"NCT06300788","title":"Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT04943237","title":"Anti-TNF Therapy and Nerve Conduction Studies in Ankylosing Spondylitis","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","has_results":false},{"nct_id":"NCT07398651","title":"Apremilast and Adalimumab in Psoriatic Arthritis Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT06165029","title":"IUS Combined With VAT Predicts Anti-TNF-α Efficacy in Patients With IBD: a Prospective Study","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"The Third Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT06906510","title":"Evaluation of Trimethylamine N-oxide (TMAO) Levels in Periodontal Disease","phase":"","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Ankara Medipol University","has_results":false},{"nct_id":"NCT06627192","title":"Effect of Non-surgical Periodontal Therapy in Hypertensive Patients With Assessment of Endocan and TNF-α Levels in GCF","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT06507592","title":"Oxidative-reductive Processes and the Degree of Inflammation in Saliva With Conventional Brackets and Clear Aligners","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":26,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false},{"nct_id":"NCT06786910","title":"Effect on Cytokines IL-1ß, TNF-α, IL-4, and Total Bacterial Load of a Composition Comprising Olive Oil, Trimethylglycine and Xylitol Delivered as a Toothpaste","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Mucosa Innovations, S.L.","has_results":false},{"nct_id":"NCT03221920","title":"Very Low Carbohydrate Diet Effects to GPS, Serum Lactate and TNF Alpha on Colorectal Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":26,"lead_sponsor_name":"Dr. Soetomo General Hospital","has_results":false},{"nct_id":"NCT06838143","title":"Ilaris NIS in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07380126","title":"The Effect of Functional Crown Lengthening Versus Deep Margin Elevation on Periodontal Tissues","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Ain Shams University","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}